8-K: MaxCyte Announces 2024 Revenue Guidance and Reaffirms 2023 Preliminary Results

MaxCyte has provided its 2024 revenue guidance, projecting flat to 5% growth in core revenue and approximately $3 million in SPL program-related revenue, while reaffirming its 2023 preliminary results.

Summary

• MaxCyte has released its preliminary financial results for 2023 and provided revenue guidance for 2024.
• Total revenue for 2023 is expected to be between $41.1 million and $41.3 million, a decrease from $44.3 million in 2022.
• Core revenue for 2023 is expected to be between $29.6 million and $29.8 million, down from $39.6 million in 2022.
• SPL Program-related revenue for 2023 is expected to be approximately $11.4 million, a significant increase from $4.6 million in 2022.
• The company expects to have approximately $210 million in cash, cash equivalents, and investments as of December 31, 2023.
• For 2024, core revenue is projected to be flat to 5% growth compared to 2023.
• SPL Program-related revenue for 2024 is expected to be approximately $3 million.
• MaxCyte anticipates ending 2024 with $175 million in total cash, cash equivalents, and investments.
• The 2024 outlook does not include SPL Program-related revenue from the sale of Vertex/CRISPRs CASGEVY.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with some positive aspects like the increase in SPL revenue in 2023 and new SPL agreements in 2024, but the overall sentiment is negative due to the decrease in total and core revenue, the significant drop in SPL revenue guidance for 2024, and the expected decrease in cash reserves.

Positives

• SPL Program-related revenue saw a significant increase in 2023, reaching approximately $11.4 million compared to $4.6 million in 2022.
• The company has a strong cash position with approximately $210 million in cash, cash equivalents, and investments expected at the end of 2023.
• MaxCyte has already signed three SPLs in 2024, indicating continued business momentum.
• The company is projecting growth in core revenue for 2024, albeit at a modest rate of flat to 5%.

Negatives

• Total revenue for 2023 is expected to decrease compared to 2022, from $44.3 million to between $41.1 million and $41.3 million.
• Core revenue for 2023 is also expected to decrease compared to 2022, from $39.6 million to between $29.6 million and $29.8 million.
• SPL Program-related revenue for 2024 is expected to decrease significantly to approximately $3 million, compared to $11.4 million in 2023.
• The company expects a decrease in total cash, cash equivalents, and investments by the end of 2024, down to $175 million from $210 million.

Risks

• The company's future performance is subject to various risks and uncertainties, including market acceptance of their technology and products.
• There are risks associated with the development, regulatory approval, and commercialization of competing products.
• The company's ability to accurately forecast and manufacture appropriate quantities of products to meet demand is a risk.
• General market and economic conditions may impact investor confidence and affect the amount of capital available to MaxCyte's partners.
• The company's financial performance and capital requirements are subject to risks.
• The company's ability to maintain intellectual property protection is a risk.

Future Outlook

MaxCyte anticipates flat to 5% growth in core revenue for 2024 and approximately $3 million in SPL program-related revenue. They expect to end 2024 with $175 million in total cash, cash equivalents, and investments. The outlook does not include SPL Program-related revenue from the sale of Vertex/CRISPRs CASGEVY.

Management Comments

• Maher Masoud, President and Chief Executive Officer at MaxCyte, stated that the company has already signed three SPLs in 2024.
• Management is confident in their ability to support current and prospective clients as new waves of next-generation cell therapies come to market.

Industry Context

The announcement comes as the cell therapy market continues to expand, with increasing adoption of non-viral delivery approaches and gene editing technologies. MaxCyte's technology is positioned to support this growth, but the company faces competition and must navigate market dynamics.

Comparison to Industry Standards

• While specific competitor data is not provided in this document, MaxCyte's revenue decline in core business and the significant drop in SPL revenue guidance for 2024 compared to 2023 suggests a potential underperformance relative to industry growth expectations.
• Companies like Lonza and Thermo Fisher Scientific, which also provide cell therapy manufacturing solutions, have been experiencing growth in this sector, making MaxCyte's results appear less robust.
• The decrease in cash reserves from $210 million to $175 million by the end of 2024 may raise concerns about the company's financial stability compared to peers with stronger cash positions.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and the lower guidance for 2024.
• Customers may be interested in the company's continued investment in its technology and platform.
• Employees may be impacted by the company's financial performance and future outlook.
• Creditors may be monitoring the company's cash position and financial stability.

Next Steps

• MaxCyte will present at the 44th Annual Cowen Conference on March 5, 2024.
• The company plans to release final financial results for the fourth quarter and full year 2023 on March 12, 2024.
• Company management will host a conference call to discuss financial results on March 12, 2024.

Key Dates

Keywords

cell engineering, electroporation, cell therapy, bioprocessing, revenue guidance, SPL program, financial results, ExPERT platform, cash position